All human studies were approved by the Yale University Institutional Review Board. Healthy control subjects (n = 2) and two patients diagnosed with GBM were recruited to participate in the DMI study. The patients (male; 63 and 67 years old) with GBM had undergone a subtotal resection of the lesion 9 and 1 month(s) before the DMI study. One patient was undergoing treatment on an experimental protocol involving nivolumab or placebo combined with the standard-of-care chemoradiation with temozolomide, followed by adjuvant temozolomide. The other patient had only received surgery before the DMI study.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.